CytRx last week reported its financial results for the fourth quarter, posting revenues of $100,000, up slightly from $90,000 in the year-ago quarter. CytRx derives its revenues from licensing its Tranzfect DNA vaccine delivery technology, which it is no longer developing in-house.
The company's net loss in the period swelled 87 percent to $5.8 million, or $0.15 per share, from $3.1 million, or $0.09 per share, in the fourth quarter of 2003.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
